Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology
Annemieke Aartsma‐Rus, Jennifer E. Morgan, Pallavi Lonkar, et al.
Journal of Neuromuscular Diseases (2019) Vol. 6, Iss. 1, pp. 147-159
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Duchenne muscular dystrophy
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 830
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision
Hendrik Neubert, Christopher M. Shuford, Timothy Olah, et al.
Clinical Chemistry (2020) Vol. 66, Iss. 2, pp. 282-301
Open Access | Times Cited: 85
Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future
Agnieszka Łoboda, Józef Dulak
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1227-1263
Open Access | Times Cited: 65
The Future of Exon Skipping for Duchenne Muscular Dystrophy
Annemieke Aartsma‐Rus
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 372-378
Closed Access | Times Cited: 21
Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy
Vratko Himič, Kay E. Davies
European Journal of Human Genetics (2021) Vol. 29, Iss. 9, pp. 1369-1376
Open Access | Times Cited: 35
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
Nicolas Wein, Tatyana A. Vetter, Adeline Vulin, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 279-293
Open Access | Times Cited: 23
What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?
Dominic J. Wells
Journal of Muscle Research and Cell Motility (2019) Vol. 40, Iss. 2, pp. 141-150
Closed Access | Times Cited: 36
Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
Jeffrey S. Chamberlain, Melissa A. Robb, Serge Braun, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 404-415
Open Access | Times Cited: 13
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
J. van Deutekom, Chantal Beekman, Suzanne Bijl, et al.
Nucleic Acid Therapeutics (2023) Vol. 33, Iss. 3, pp. 193-208
Open Access | Times Cited: 13
Morpholino oligonucleotide-mediated exon skipping for DMD treatment: Past insights, present challenges and future perspectives
Shalini Gupta, Swrajit Nath Sharma, Jayanta Kundu, et al.
Journal of Biosciences (2023) Vol. 48, Iss. 4
Closed Access | Times Cited: 13
Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy
Alicja Starosta, Patryk Konieczny
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 11, pp. 4867-4891
Open Access | Times Cited: 27
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Ahlke Heydemann, Grzegorz Biegański, Jacek Wachowiak, et al.
Stem Cell Reviews and Reports (2023) Vol. 19, Iss. 5, pp. 1340-1359
Open Access | Times Cited: 10
A historical perspective on the development of antisense oligonucleotide treatments for Duchenne muscular dystrophy and spinal muscular atrophy
Annemieke Aartsma‐Rus, Shin’ichi Takeda
Journal of Neuromuscular Diseases (2025)
Closed Access
Antisense RNA therapies for muscular dystrophies
Virginia Arechavala‐Gomeza, Andrea López‐Martínez, Annemieke Aartsma‐Rus
Journal of Neuromuscular Diseases (2025)
Closed Access
Advances in Duchenne Muscular Dystrophy: Diagnostic Techniques and Dystrophin Domain Insights
Julija Sarvutiene, Arūnas Ramanavičius, Simonas Ramanavičius, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3579-3579
Open Access
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Theodora Markati, Liesbeth De Waele, Urlike Schara-Schmidt, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 23
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease
Craig M. McDonald, Eric Camino, Rafael Escandon, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 499-523
Open Access | Times Cited: 3
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy
Anne-Fleur Schneider, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 3, pp. 343-359
Open Access | Times Cited: 21
Quantitative immuno-mass spectrometry imaging of skeletal muscle dystrophin
David Bishop, Mika T. Westerhausen, Florian Barthélémy, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 20
Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy
James S. Novak, Rita Spathis, Utkarsh J. Dang, et al.
Journal of Neuromuscular Diseases (2021) Vol. 8, Iss. s2, pp. S383-S402
Open Access | Times Cited: 20
A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples
Valentina Sardone, Matthew Ellis, Silvia Torelli, et al.
PLoS ONE (2018) Vol. 13, Iss. 3, pp. e0194540-e0194540
Open Access | Times Cited: 21
Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay
Zaïda Koeks, Annika Janson, Chantal Beekman, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Guidelines for genetic testing of muscle and neuromuscular junction disorders
Stefan Nicolau, Margherita Milone, Teerin Liewluck
Muscle & Nerve (2021) Vol. 64, Iss. 3, pp. 255-269
Closed Access | Times Cited: 17
Bioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics: Regulatory Expectations
Boris Gorovits, Jean‐Claude Marshall, Justin Smith, et al.
Bioanalysis (2019) Vol. 11, Iss. 21, pp. 2011-2024
Closed Access | Times Cited: 19
Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models
Florian Barthélémy, Richard T. Wang, Christopher P. Hsu, et al.
Molecular Therapy — Nucleic Acids (2019) Vol. 18, pp. 580-589
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top